340 related articles for article (PubMed ID: 33554636)
1. Darolutamide and survival in nonmetastatic, castration-resistant prostate cancer: a patient perspective of the ARAMIS trial.
Fizazi K; Blue I; Nowak JT
Future Oncol; 2021 May; 17(14):1699-1707. PubMed ID: 33554636
[TBL] [Abstract][Full Text] [Related]
2. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial.
Smith MR; Hussain M; Saad F; Fizazi K; Sternberg CN; Crawford D; Manarite J; Muslin D; Farrington T; Tombal B
Future Oncol; 2022 Jul; 18(21):2585-2597. PubMed ID: 35656777
[TBL] [Abstract][Full Text] [Related]
3. Darolutamide in Spanish patients with nonmetastatic castration-resistant prostate cancer: ARAMIS subgroup analysis.
Carles J; Medina-Lopez RA; Puente J; Gómez-Ferrer Á; Nebra JC; Sáez Medina MI; Ribal MJ; Antolín AR; Álvarez-Ossorio JL; Suárez Novo JF; Agut CM; Srinivasan S; Ortiz J; Fizazi K
Future Oncol; 2023 Apr; 19(12):819-828. PubMed ID: 37222151
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial.
Shore N; Zurth C; Fricke R; Gieschen H; Graudenz K; Koskinen M; Ploeger B; Moss J; Prien O; Borghesi G; Petrenciuc O; Tammela TL; Kuss I; Verholen F; Smith MR; Fizazi K
Target Oncol; 2019 Oct; 14(5):527-539. PubMed ID: 31571095
[TBL] [Abstract][Full Text] [Related]
5. Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.
Fizazi K; Shore N; Tammela TL; Ulys A; Vjaters E; Polyakov S; Jievaltas M; Luz M; Alekseev B; Kuss I; Le Berre MA; Petrenciuc O; Snapir A; Sarapohja T; Smith MR;
N Engl J Med; 2020 Sep; 383(11):1040-1049. PubMed ID: 32905676
[TBL] [Abstract][Full Text] [Related]
6. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
Fizazi K; Shore N; Tammela TL; Ulys A; Vjaters E; Polyakov S; Jievaltas M; Luz M; Alekseev B; Kuss I; Kappeler C; Snapir A; Sarapohja T; Smith MR;
N Engl J Med; 2019 Mar; 380(13):1235-1246. PubMed ID: 30763142
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial.
Bögemann M; Shore ND; Smith MR; Tammela TLJ; Ulys A; Vjaters E; Polyakov S; Jievaltas M; Luz M; Alekseev B; Lebret T; Schostak M; Verholen F; Le Berre MA; Srinivasan S; Ortiz J; Mohamed AF; Sarapohja T; Fizazi K
Eur Urol; 2023 Mar; 83(3):212-221. PubMed ID: 36089529
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety outcomes of darolutamide in patients with non-metastatic castration-resistant prostate cancer with comorbidities and concomitant medications from the randomised phase 3 ARAMIS trial.
Fizazi K; Shore ND; Smith M; Ramos R; Jones R; Niegisch G; Vjaters E; Wang Y; Srinivasan S; Sarapohja T; Verholen F
Eur J Cancer; 2023 Oct; 192():113258. PubMed ID: 37660438
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial.
Uemura H; Matsushima H; Kobayashi K; Mizusawa H; Nishimatsu H; Fizazi K; Smith M; Shore N; Tammela T; Tabata KI; Matsubara N; Iinuma M; Uemura H; Oya M; Momma T; Kawakita M; Fukasawa S; Kobayashi T; Kuss I; Le Berre MA; Snapir A; Sarapohja T; Suzuki K
Int J Clin Oncol; 2021 Mar; 26(3):578-590. PubMed ID: 33226524
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of darolutamide in Black/African-American patients from the phase III ARAMIS study.
Shore ND; Cruz F; Nordquist L; Belkoff L; Aronson WJ; Tolia B; Cinman A; Sharifi R; Ortiz J; Parkin J; Srinivasan S; Sarapohja T; Smith MR
Future Oncol; 2022 Dec; 18(40):4473-4482. PubMed ID: 36753353
[TBL] [Abstract][Full Text] [Related]
11. Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial.
Smith MR; Shore N; Tammela TL; Ulys A; Vjaters E; Polyakov S; Jievaltas M; Luz M; Alekseev B; Kuss I; Le Berre MA; Mohamed AF; Odom D; Bartsch J; Snapir A; Sarapohja T; Fizazi K
Eur J Cancer; 2021 Sep; 154():138-146. PubMed ID: 34273811
[TBL] [Abstract][Full Text] [Related]
12. Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.
Fizazi K; Smith MR; Tombal B
Clin Genitourin Cancer; 2018 Oct; 16(5):332-340. PubMed ID: 30197098
[TBL] [Abstract][Full Text] [Related]
13. Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison.
Chowdhury S; Oudard S; Uemura H; Joniau S; Dearden L; Capone C; Van Sanden S; Diels J; Hadaschik BA
Adv Ther; 2022 Jan; 39(1):518-531. PubMed ID: 34797506
[TBL] [Abstract][Full Text] [Related]
14. Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer.
Appukkuttan S; Farej R; Miles L; Purser M; Wen L
J Manag Care Spec Pharm; 2021 Feb; 27(2):166-174. PubMed ID: 33141615
[No Abstract] [Full Text] [Related]
15. Impact of darolutamide on local symptoms: pre-planned and post hoc analyses of the ARAMIS trial.
Shore ND; Stenzl A; Pieczonka C; Klaassen Z; Aronson WJ; Karsh L; Ryan CJ; Ortiz J; Srinivasan S; Mohamed AF; Verholen F
BJU Int; 2023 Apr; 131(4):452-460. PubMed ID: 36087070
[TBL] [Abstract][Full Text] [Related]
16. [Darolutamide: A new drug for non-metastatic castration-resistant prostate cancer].
Zhang F; Lu YP
Zhonghua Nan Ke Xue; 2020 Apr; 26(4):364-368. PubMed ID: 33351306
[TBL] [Abstract][Full Text] [Related]
17. Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.
Halabi S; Jiang S; Terasawa E; Garcia-Horton V; Ayyagari R; Waldeck AR; Shore N
J Urol; 2021 Aug; 206(2):298-307. PubMed ID: 33818140
[TBL] [Abstract][Full Text] [Related]
18. Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.
Scott LJ
Target Oncol; 2020 Dec; 15(6):791-799. PubMed ID: 33237495
[TBL] [Abstract][Full Text] [Related]
19. Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction.
Esther J; Maughan BL; Anderson N; Agarwal N; Hahn AW
Curr Treat Options Oncol; 2019 Feb; 20(2):14. PubMed ID: 30741354
[TBL] [Abstract][Full Text] [Related]
20. Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS.
Shore ND; Gratzke C; Feyerabend S; Werbrouck P; Carles J; Vjaters E; Tammela TLJ; Morris D; Aragon-Ching JB; Concepcion RS; Emmenegger U; Fleshner N; Grabbert M; Lietuvietis V; Mahammedi H; Cruz FM; Paula A; Pieczonka C; Rannikko A; Richardet M; Silveira G; Kuss I; Le Berre MA; Verholen F; Sarapohja T; Smith MR; Fizazi K
Oncologist; 2024 Feb; ():. PubMed ID: 38394384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
